These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 16838606)

  • 21. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
    Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Contemporary survival results and the role of radiation therapy in patients with node negative seminal vesicle invasion following radical prostatectomy.
    Eggener SE; Roehl KA; Smith ND; Antenor JA; Han M; Catalona WJ
    J Urol; 2005 Apr; 173(4):1150-5. PubMed ID: 15758725
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Seminal vesicle involvement in patients with D1 disease predicts early prostate specific antigen recurrence and metastasis after radical prostatectomy and early androgen ablation.
    Ahlering TE; Skarecky DW; McLaren CE; Weinberg AC
    Cancer; 2002 Mar; 94(6):1648-53. PubMed ID: 11920524
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer.
    Tefilli MV; Gheiler EL; Tiguert R; Banerjee M; Sakr W; Grignon DJ; Pontes JE; Wood DP
    J Urol; 1998 Sep; 160(3 Pt 1):802-6. PubMed ID: 9720552
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer.
    Khan MA; Partin AW; Mangold LA; Epstein JI; Walsh PC
    Urology; 2003 Nov; 62(5):866-71. PubMed ID: 14624910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.
    D'amico AV; Tempany CM; Schultz D; Cormack RA; Hurwitz M; Beard C; Albert M; Kooy H; Jolesz F; Richie JP
    Urology; 2003 Dec; 62(6):1063-7. PubMed ID: 14665356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.
    Bhatta-Dhar N; Reuther AM; Zippe C; Klein EA
    Urology; 2004 Mar; 63(3):528-31. PubMed ID: 15028451
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Amling CL; Dorey F; Kane CJ; Presti JC; Terris MK; Aronson WJ;
    Urology; 2002 Oct; 60(4):670-4. PubMed ID: 12385931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radical prostatectomy and positive surgical margins: relationship with prostate cancer outcome.
    De La Roca RL; Da Cunha IW; Bezerra SM; Da Fonseca FP
    Int Braz J Urol; 2014; 40(3):306-15. PubMed ID: 25010296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients.
    Salomon L; Hoznek A; Lefrère-Belda MA; Bellot J; Chopin DK; Abbou CC
    Eur Urol; 2000 Mar; 37(3):297-300. PubMed ID: 10720855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup.
    Palapattu GS; Allaf ME; Trock BJ; Epstein JI; Walsh PC
    J Urol; 2004 Nov; 172(5 Pt 1):1860-4. PubMed ID: 15540739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy.
    Kamat AM; Babaian K; Cheung MR; Naya Y; Huang SH; Kuban D; Babaian RJ
    J Urol; 2003 Nov; 170(5):1860-3. PubMed ID: 14532793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrence after radical prostatectomy for organ-confined prostate cancer.
    Scheepe JR; Vis AN; Mickisch GH
    Onkologie; 2003 Aug; 26(4):330-3. PubMed ID: 12972697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Schnall M; Tomaszewski JE; Wein A
    J Urol; 1995 Jul; 154(1):131-8. PubMed ID: 7539857
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of free to total PSA ratio in prediction of extracapsular tumor extension and biochemical recurrence after radical prostatectomy in patients with PSA between 4 and 10 ng/ml.
    Masieri L; Minervini A; Vittori G; Lanciotti M; Lanzi F; Lapini A; Carini M; Serni S
    Int Urol Nephrol; 2012 Aug; 44(4):1031-8. PubMed ID: 22315156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate specific antigen outcome based on the extent of extracapsular extension and margin status in patients with seminal vesicle negative prostate carcinoma of Gleason score < or = 7.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Tomaszewski JE; Wein A
    Cancer; 2000 May; 88(9):2110-5. PubMed ID: 10813723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.